I have been the Operations manager for the Future Vaccine Manufacturing Hub (https://www.imperial.ac.uk/future-vaccine-hub) in the lab of Robin Shattock since 2022. This strategic partnership of researchers, national centres and industry, aims to revolutionise vaccine manufacturing, with a particular focus on LMIC.I am also an Hon Associate Professor at UCL.
I completed a PhD in immunology and Genetics at Cambridge with Geoff Butcher in 1995 and an MSc in Epidemiology at Imperial College in 2007. I have diverse experience in the lab and field and a wide interest in public health. I have worked in vaccines since 2007 and remain primarily focussed on the search and delivery of equitable public health interventions . My move from the lab into clinical immunology came after life changing experiences in South Africa and Namibia and an MSc in Modern Epidemiology in 2007. I then had the good fortune work with Sheena McCormack and have >15 years experience working in clinical trials for infectious disease such as HIV, Covid-19 and Lassa fever. I have been able to remain involved in HIV prevention throughout; most recently through PrEPVacc (PrEPVacc.org) - the first ever European funded Phase IIb vaccine trial. I am involved in the Imperial network for Vaccine research (https://www.imperial.ac.uk/vaccine-research-network).
I am committed to improving vaccine literacy (https://www.iavi.org/news-resources/iavi-vaccine-literacy-library) and supported Covid-19 outreach activities for the BSI in 2021
I have lived and worked in Namibia, South Africa, Uganda, Kenya, Mozambique and Tanzania and remain committed to and involved in supporting scientific research in those countries. I have field experience in Schistosomiasis, Malaria, TB and HIV research in endemic countries.
I continue to learn from all my far flung collaborators and am very interested in all aspects of all cultures. I am a trustee of the Volunteer Centre Greenwich and a very enthusiastic printmaker.
et al., 2023, A phase I COVID-19 vaccine trial among SARS-CoV-2 seronegative and seropositive individuals in Uganda utilizing a self-amplifying RNA vaccine platform: screening and enrollment experiences, Human Vaccines and Immunotherapeutics, Vol:19, ISSN:1554-8600, Pages:1-8
et al., 2023, Systematic comparison of HIV-1 Envelope-specific IgG responses induced by different vaccination regimens: Can we steer IgG recognition towards regions of viral vulnerability?, Frontiers in Immunology, Vol:13, ISSN:1664-3224, Pages:1-16
et al., 2022, Optimization and validation of an ELISA assay for the determination of antibody responses to CN54gp140 and AIDSVAX BE for use in the Phase IIb PrEPVacc vaccine trial, Plos One, Vol:17, ISSN:1932-6203
et al., 2021, HIV-1 infection and the lack of viral control are associated with greater expression of interleukin-21 receptor on CD8(+) T cells, Aids, Vol:35, ISSN:0269-9370, Pages:1167-1177
et al., 2021, A novel sample selection approach to aid the identification of factors that correlate wth the control of HIV-1 infection, Frontiers in Immunology, Vol:12, ISSN:1664-3224, Pages:1-12